The risk and natural course of age-related maculopathy: Follow-up at 6 1/2 years in the Rotterdam study

Archives of Ophthalmology

Volumn 121, Issue 4, 2003, Pages 519-526

  Van Leeuwen, Redmer ^a   Klaver, Caroline C W ^a   Vingerling, Johannes R ^a   Hofman, Albert ^a   De Jong, Paulus T V M ^a,b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUSEN; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULOPATHY; RISK FACTOR; STEREOSCOPIC VISION;

AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037388460     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.4.519     Document Type: Article

References (14)

1. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study, I: outline and major prevalence findings. Am J Epidemiol. 1977;106:17-32.
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
3. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205-210.
4. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. Ophthalmology. 1995;102:1450-1460.
5. Klein R, Clegg L, Cooper LS, et al. Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study. Arch Ophthalmol. 1999;117:1203-1210.
6. Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001; 42:2237-2241.
7. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403-422.
8. The International ARM Epidemiological Study Group. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol. 1995;39:367-374.
9. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1998.
10. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104:7-21.
11. Bressler SB, Maguire MG, Bressler NM, Fine SL, for the Macular Photocoagulation Study Group. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Arch Ophthalmol. 1990;108:1442-1447.
12. Holz FG, Wolfensberger TJ, Piguet B, et al. Bilateral macular drusen in age-related macular degeneration: prognosis and risk factors. Ophthalmology. 1994; 101:1522-1528.
13. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.
14. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108:697-704.